Share-based Payment Arrangement, Expense in USD of PROVECTUS BIOPHARMACEUTICALS, INC. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Provectus Biopharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2010 to Q3 2025.
  • Provectus Biopharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $313K, a 67.1% decline year-over-year.
  • Provectus Biopharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $1.28M.
  • Provectus Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1.28M.
  • Provectus Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2016 was $0.000, a 100% decline from 2015.
  • Provectus Biopharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2015 was $671K, a 480% increase from 2014.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.28M $313K -$637K -67.1% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $1.92M $322K +$322K Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $1.6M $315K +$315K Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $1.28M $331K Oct 1, 2024 Dec 31, 2024 10-K 2025-03-28
Q3 2024 $949K Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $0 Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q3 2014 $116K -$26.7K -18.7% Jul 1, 2014 Sep 30, 2014 10-Q 2014-11-06
Q3 2013 $142K +$142K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-06
Q3 2012 $0 -$3.37M -100% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-12
Q2 2012 $183K +$183K Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-08
Q3 2011 $3.37M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-08
Q2 2011 $0 Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-08

PROVECTUS BIOPHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.28M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-28
2016 $0 -$671K -100% Jan 1, 2016 Dec 31, 2016 10-K 2017-03-31
2015 $671K +$555K +480% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-31
2014 $116K -$26.7K -18.7% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-31
2013 $142K -$40.7K -22.2% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-30
2012 $183K -$3.19M -94.6% Jan 1, 2012 Dec 31, 2012 10-K 2015-03-12
2011 $3.37M -$391K -10.4% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-13
2010 $3.76M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.